You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Of the 31 companies in the index, 11 firms saw their stock prices increase, while 20 saw their share prices decline.
Revenues were down year-over-year because of an international capital deal in the fourth quarter of 2019 that did not repeat in the current year.
With new platforms in its plans, Accelerate will target hospitals that have a bacterial identification method but want to add rapid susceptibility testing.
Exact Sciences discussed newly released data and its plans for Cologuard, while Luminex provided details about its warning letter from the FDA.
During the quarter, the Tucson, Arizona-based company added 45 instruments for a total of 268 revenue-generating instruments installed in the US.
Not every company in the 360Dx Index had significant gains, but multiple companies saw their share prices double.
Quidel and Accelerate Diagnostics had the biggest declines in their share prices as the Index lagged behind the broader markets.
The firm saw durable consumables revenue in Q3, added five contracted instruments in the quarter, and brought 22 new instruments live in the US.
The European Commission recently awarded the company a two-year, €2.6 million Horizon 2020 grant to achieve its ambitions.
Fujirebio Diagnostics got the nod for a chemiluminescent enzyme immunoassay to measure levels of CA 15-3 and manage patients diagnosed with breast cancer.